Infusio Updates Integrative Lyme Disease Program 2018

Infusio / All  / Infusio Updates Integrative Lyme Disease Program 2018

Infusio Updates Integrative Lyme Disease Program 2018

Infusio is happy to announce to changes and updates to its Integrative Lyme Disease Program starting 2018. These changes will be effective for any patients booked for a program starting on January 8 or after. Also, past patients may benefit from some of the changes in the new program. Up until the end of 2017, the program consisted of a 10 or 11-day treatment program consisting of multiple IV treatments, SVF cell therapy and supportive treatments. A follow up consultation was then performed approximately 4 month later. As Lyme Disease is an ever-changing picture, the 2018 program has been updated and augmented to reflect our resolve to offer our patients the new, cutting-edge tools as part of a treatment regimen.

What Are the Changes?

The most important change is the addition of a four day follow up program, including a Global Diagnostics consultation, Hormone consultation, some supportive IVs and the application of ACT (autologous cyto-immunotherapy). In Germany, patients will be required to stay for 5 days. To facilitate the consultation, patients will be required to obtain a CBC, hormone panel and a thyroid panel before taking part in the follow up program. Please contact the Infusio office to see if the doctor requires any other blood work for your consultation. The program will always start on a Monday.

During the ‘100-day’ adaptive period, patients will now have much to do. This time will focus on supporting detoxification processes and intestinal restoration. A basic, take home program will be provided. In some cases, additional supplements outside of the program may be recommended.

Patients will also be supported through a stronger online presence. They will receive weekly videos offering support and tips specific for the recovery phase after receiving SVF. Also, bi-weekly information will be posted on the Infusio Exchange group site. In future, patients will receive an app through which these services can be accessed.

Follow up phone calls will also be restructured. Most patients will be able to access the online schedule through their patient portal and schedule their preferred time for a follow up phone call. This will avoid the many missed calls and telephone tag of the past.

The ten-day IV program will also be restructured. This will allow for more obvious individualization of the program, further accommodating the individual needs of the patients.

As part of the pre-program work up, patients will be asked to list their five most important symptoms. This information will be used as the treatment focuses on providing relief for these

symptoms. These symptoms will also be used to track progress and provide other supportive treatments. These results will also be entered into a data bank to help collect information and statistics for future patients.

What Are the Costs?

For 2018 patients, there will be no increase in the cost of the program. This will remain as in 2017. Due to new developments on the scientific side and product processes, it has been possible to reduce the overall cost of the program. Instead of passing this on as a direct cost reduction, it was decided to incorporate procedures which were planned to be add on features of the program, into the main program at no further charge. Patients who took part in the 2017 program after September 1, 2017 will also receive the ACT program free of charge. For patients, outside of this time frame, there may be a minimal charge for the follow up program.

What is ACT?

ACT is a blood derived cell therapy utilizing cells and information found in a patient’s immune system and potentiate its activity. This extract can contain hematopoietic stem cells, mesenchymal stem cells, dendritic cells, lymphocytes (T cells, B cells, NK cells) monocytes as well as a range of growth factors. It may be expanded in the lab, and can be modified to enhance specific components or cell lines already contained in the extract. The ACT is re-administered as an IV infusion lasting a few minutes. For the patient, ACT is as simple as a blood draw followed by an IV infusion given hours or several days later.

Infusio sincerely hope that these changes will offer patient a more comprehensive, individualized treatment program thus improving patient outcomes.

Share